Integrated genomic analyses of ovarian carcinoma
Mayo Clinic · WinnMed · +60 more institutions
Abstract
A catalogue of molecular aberrations that cause ovarian cancer is critical for developing and deploying therapies that will improve patients’ lives. The Cancer Genome Atlas project has analysed messenger RNA expression, microRNA expression, promoter methylation and DNA copy number in 489 high-grade serous ovarian adenocarcinomas and the DNA sequences of exons from coding genes in 316 of these tumours. Here we report that high-grade serous ovarian cancer is characterized by TP53 mutations in almost all tumours (96%); low prevalence but statistically recurrent somatic mutations in nine further genes including NF1, BRCA1, BRCA2, RB1 and CDK12; 113 significant focal DNA copy number aberrations; and promoter…
Citation impact
- FWCI
- 177.40
- Percentile
- 100%
- References
- 57
Authors
310- DBDebra BellCorresponding
Mayo Clinic, WinnMed, Mayo Clinic in Arizona
- ABAndrew Berchuck
Duke University, Duke Medical Center
- ABAndrew Berchuck
Duke University, Harvard University Press, Duke Medical Center
- MJMichael J. Birrer
Mayo Clinic, Harvard University, WinnMed, Massachusetts General Hospital
- MIMarcin Imieliński
Harvard University Press, Massachusetts General Hospital
Topics & keywords
- Ovarian cancer
- Biology
- microRNA
- DNA methylation
- Exon
- Gene
- Cancer research
- Serous fluid
- Good health and well-being